ergocalciferols

Summary

Summary: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.

Top Publications

  1. ncbi Vitamin D analogues for secondary hyperparathyroidism
    Alex J Brown
    Renal Division, Washington University School of Medicine, St Louis, Missouri, USA
    Nephrol Dial Transplant 17:10-9. 2002
  2. ncbi Mortality risk among hemodialysis patients receiving different vitamin D analogs
    F Tentori
    Dialysis Clinic Inc, Albuquerque, New Mexico, USA
    Kidney Int 70:1858-65. 2006
  3. ncbi Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis
    Edward A Ross
    Division of Nephrology, Hypertension, and Transplantation, University of Florida, Gainesville, FL 32610 0224, USA
    Am J Nephrol 28:97-106. 2008
  4. ncbi Activated injectable vitamin D and hemodialysis survival: a historical cohort study
    Ming Teng
    Fresenius Medical Care North America, Lexington, Massachusetts, USA
    J Am Soc Nephrol 16:1115-25. 2005
  5. ncbi Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy
    Ming Teng
    Fresenius Medical Care North America, Lexington, Mass, USA
    N Engl J Med 349:446-56. 2003
  6. doi Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial
    Ravi Thadhani
    Division of Nephrology, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA
    JAMA 307:674-84. 2012
  7. pmc Vitamin D receptor activators can protect against vascular calcification
    Suresh Mathew
    Department of Pediatrics, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Am Soc Nephrol 19:1509-19. 2008
  8. ncbi Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients
    K Kalantar-Zadeh
    Division of Nephrology and Hypertension, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California 90502, USA
    Kidney Int 70:771-80. 2006
  9. pmc Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D
    Michael F Holick
    Department of Medicine, Boston University School of Medicine, 715 Albany Street, M 1013, Boston, Massachusetts 02118, USA
    J Clin Endocrinol Metab 93:677-81. 2008
  10. doi Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism
    Katherine Wesseling-Perry
    Division of Pediatric Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Kidney Int 79:112-9. 2011

Research Grants

Detail Information

Publications239 found, 100 shown here

  1. ncbi Vitamin D analogues for secondary hyperparathyroidism
    Alex J Brown
    Renal Division, Washington University School of Medicine, St Louis, Missouri, USA
    Nephrol Dial Transplant 17:10-9. 2002
    ..A clear understanding of the molecular basis for the selectivity of vitamin D analogues on parathyroid function may allow the design of even more effective analogues...
  2. ncbi Mortality risk among hemodialysis patients receiving different vitamin D analogs
    F Tentori
    Dialysis Clinic Inc, Albuquerque, New Mexico, USA
    Kidney Int 70:1858-65. 2006
    ..2 (1.1-1.3)). Mortality in doxercalciferol- and paricalcitol-treated patients was virtually identical. Differences in survival between vitamin D2 and D3 may be smaller than previously reported...
  3. ncbi Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis
    Edward A Ross
    Division of Nephrology, Hypertension, and Transplantation, University of Florida, Gainesville, FL 32610 0224, USA
    Am J Nephrol 28:97-106. 2008
    ..This study investigates the effects of oral paricalcitol to reduce PTH in patients receiving chronic HD and peritoneal dialysis (PD)...
  4. ncbi Activated injectable vitamin D and hemodialysis survival: a historical cohort study
    Ming Teng
    Fresenius Medical Care North America, Lexington, Massachusetts, USA
    J Am Soc Nephrol 16:1115-25. 2005
    ..Randomized clinical trials would permit definitive conclusions...
  5. ncbi Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy
    Ming Teng
    Fresenius Medical Care North America, Lexington, Mass, USA
    N Engl J Med 349:446-56. 2003
    ..Paricalcitol, a new vitamin D analogue, appears to lessen the elevations in serum calcium and phosphorus levels, as compared with calcitriol, the standard form of injectable vitamin D...
  6. doi Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial
    Ravi Thadhani
    Division of Nephrology, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA
    JAMA 307:674-84. 2012
    ..Vitamin D is associated with decreased cardiovascular-related morbidity and mortality, possibly by modifying cardiac structure and function, yet firm evidence for either remains lacking...
  7. pmc Vitamin D receptor activators can protect against vascular calcification
    Suresh Mathew
    Department of Pediatrics, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Am Soc Nephrol 19:1509-19. 2008
    ..We conclude that low, clinically relevant dosages of calcitriol and paricalcitol may protect against CKD-stimulated vascular calcification...
  8. ncbi Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients
    K Kalantar-Zadeh
    Division of Nephrology and Hypertension, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, California 90502, USA
    Kidney Int 70:771-80. 2006
    ....
  9. pmc Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D
    Michael F Holick
    Department of Medicine, Boston University School of Medicine, 715 Albany Street, M 1013, Boston, Massachusetts 02118, USA
    J Clin Endocrinol Metab 93:677-81. 2008
    ..Two reports suggested that vitamin D2 is less effective than vitamin D3 in maintaining vitamin D status...
  10. doi Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism
    Katherine Wesseling-Perry
    Division of Pediatric Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    Kidney Int 79:112-9. 2011
    ..Sevelamer allows the use of higher doses of vitamin D. Implications of these changes on bone and cardiovascular biology remain to be established...
  11. pmc Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury
    Weichun He
    Department of Pathology, University of Pittsburgh School of Medicine, S 405 Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, PA 15261, USA
    J Am Soc Nephrol 22:90-103. 2011
    ..In summary, these findings suggest that paricalcitol prevents podocyte dysfunction, proteinuria, and kidney injury in adriamycin nephropathy by inhibiting Wnt/β-catenin signaling...
  12. ncbi Antiproteinuric effect of oral paricalcitol in chronic kidney disease
    Rajiv Agarwal
    Indiana University School of Medicine and Richard L Roudebush VA Medical Center, Indianapolis, IN 46202, USA
    Kidney Int 68:2823-8. 2005
    ..While active vitamin D and its analogs have been shown to have renal protective effects in animals, these hormones have not been shown to reduce proteinuria in CKD patients...
  13. doi Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis
    Jun Cheng
    Kidney Disease Center, The First Affiliated Hospital, Medical School of Zhejiang University, Hangzhou, China
    Clin J Am Soc Nephrol 7:391-400. 2012
    ..To systematically evaluate the efficacy and safety of paricalcitol for CKD, we conducted a meta-analysis of the published randomized controlled trials (RCTs)...
  14. doi Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats
    Jane L Finch
    Renal Div, Box 8126, Washington Univ School of Medicine, St Louis, MO 63110, USA
    Am J Physiol Renal Physiol 302:F141-9. 2012
    ....
  15. doi Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial
    Pooneh Alborzi
    Indiana University and VAMC, 1481 W 10th St, Indianapolis, IN 46202, USA
    Hypertension 52:249-55. 2008
    ..Long-term randomized, controlled trials are required to confirm these benefits of vitamin D analogs...
  16. doi Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol
    Paul Glendenning
    Department of Core Clinical Pathology and Biochemistry, PathWest Royal Perth Hospital, Perth, Western Australia 6000, Australia
    Bone 45:870-5. 2009
    ..However, the lack of difference in PTH lowering between calciferol treatments raises questions about the biological importance of this observation...
  17. doi Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly
    Elisabetta Romagnoli
    Department of Clinical Sciences, University of Rome Sapienza, Viale del Policlinico 155, 00161 Rome, Italy
    J Clin Endocrinol Metab 93:3015-20. 2008
    ..In humans, few studies have compared the potencies of ergocalciferol and cholecalciferol in improving and maintaining vitamin D status...
  18. ncbi Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD
    Daniel Coyne
    Renal Division, Department of Internal Medicine, Chromalloy American Kidney Center, Washington University, St Louis, MO, USA
    Am J Kidney Dis 47:263-76. 2006
    ..The capsule form of paricalcitol was developed to provide a convenient dosage form for patients with stages 3 and 4 CKD...
  19. pmc Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats
    Juan Kong
    Laboratory of Metabolic Disease Research and Drug Development, Shengjing Hospital, China Medical University, Shenyang, China
    Am J Pathol 177:622-31. 2010
    ....
  20. doi Paricalcitol attenuates cyclosporine-induced kidney injury in rats
    Jeong Woo Park
    Department of Internal Medicine, Chonnam National University Medical School, Gwangju 501 757, Korea
    Kidney Int 77:1076-85. 2010
    ....
  21. pmc Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling
    Xiaoyue Tan
    Division of Cellular and Molecular Pathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA
    J Am Soc Nephrol 19:1741-52. 2008
    ..These results suggest that paricalcitol inhibits renal inflammatory infiltration and RANTES expression by promoting VDR-mediated sequestration of NF-kappaB signaling...
  22. ncbi Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease
    Dennis L Andress
    University of Washington School of Medicine, Seattle, Washington, USA
    Endocr Pract 14:18-27. 2008
    ..To review approved treatment options for secondary hyperparathyroidism (SHPT) in patients with stages 3 and 4 chronic kidney disease (CKD)...
  23. doi Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats
    Kazim Husain
    Department of Physiology, Pharmacology and Toxicology, Ponce School of Medicine, Ponce, PR 00732, USA
    Am J Nephrol 29:465-72. 2009
    ..This study investigated the protective effect of the angiotensin-converting enzyme inhibitor, enalapril, and the vitamin D analog, paricalcitol, alone or in combination, on cardiac oxidative stress in uremic rats...
  24. doi Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells
    Klára Sochorová
    Institute of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, V Uvalu 84, 150 06 Prague, Czech Republic
    Clin Immunol 133:69-77. 2009
    ..The immunomodulatory potency of paricalcitol makes it a drug of interest in the therapy of chronic immune-mediated inflammatory diseases...
  25. doi Vitamin D(3) is more potent than vitamin D(2) in humans
    Robert P Heaney
    Creighton University, 601 North 30th Street, Suite 4841, Omaha, Nebraska 68131, USA
    J Clin Endocrinol Metab 96:E447-52. 2011
    ..Current unitage for the calciferols suggests that equimolar quantities of vitamins D(2) (D2) and D(3) (D3) are biologically equivalent. Published studies yield mixed results...
  26. doi Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas
    Kazim Husain
    Department of Physiology, Pharmacology and Toxicology, Ponce School of Medicine, P R, USA
    Am J Nephrol 32:296-304. 2010
    ..This study investigated the protective effect of vitamin D analog paricalcitol combined with angiotensin-converting enzyme inhibitor (enalapril) on aortic oxidative injury in atherosclerotic mice...
  27. ncbi Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment
    Melanie S Joy
    School of Medicine, Division of Nephrology and Hypertension, UNC Kidney Center, Univerisity of North Carolina, Chapel Hill, NC 27599 7155, USA
    J Manag Care Pharm 13:397-411. 2007
    ..The number of patients who will be identified and prescribed therapies for complications such as secondary hyperparathyroidism (SHPT) is greater than initially proposed...
  28. pmc Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase
    Zhongyi Zhang
    Department of Medicine, Division of Biological Sciences, University of Chicago, Chicago, IL 60637, USA
    Proc Natl Acad Sci U S A 105:15896-901. 2008
    ..These data demonstrate that inhibition of the RAS with combination of vitamin D analogs and RAS inhibitors effectively prevents renal injury in diabetic nephropathy...
  29. doi Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients
    Richard J Lund
    Department of Medicine, Creighton University, 3316 Dodge Street, Omaha, NE 68154, USA
    Am J Nephrol 31:165-70. 2010
    ..This study compared intestinal Ca absorption in hemodialysis patients treated with calcitriol versus paricalcitol (dose ratio 1:3)...
  30. ncbi The case against ergocalciferol (vitamin D2) as a vitamin supplement
    Lisa A Houghton
    School of Nutrition and Dietetics, Acadia University, Wolfville, Canada
    Am J Clin Nutr 84:694-7. 2006
    ..Vitamin D2, or ergocalciferol, should not be regarded as a nutrient suitable for supplementation or fortification...
  31. doi Vitamin D receptor activation in a diabetic-like environment: potential role in the activity of the endothelial pro-inflammatory and thioredoxin pathways
    T Zitman-Gal
    Renal Physiology Laboratory, Department of Nephrology and Hypertension, Meir Medical Center, Kfar Saba, Israel
    J Steroid Biochem Mol Biol 132:1-7. 2012
    ..In this in vitro study, it seems that the TRX antioxidant system was not involved. The different effects found between paricalcitol and calcitriol might reflect the selectivity of vitamin D receptor (VDR) activation...
  32. pmc Fortification of orange juice with vitamin D(2) or vitamin D(3) is as effective as an oral supplement in maintaining vitamin D status in adults
    Rachael M Biancuzzo
    Department of Medicine, Boston University School of Medicine, MA, USA
    Am J Clin Nutr 91:1621-6. 2010
    ..Vitamin D has been added to calcium-fortified orange juice. It is unknown whether vitamin D is as bioavailable from orange juice as it is from supplements...
  33. pmc Integrated genomics of ovarian xenograft tumor progression and chemotherapy response
    Ashley Stuckey
    Molecular Therapeutics Laboratory, Program in Women s Oncology, Department of Obstetrics and Gynecology, Women and Infants7 Hospital, Alpert Medical School of Brown University, Providence, RI 02905, USA
    BMC Cancer 11:308. 2011
    ..In this study we identify genes and gene networks important for the efficacy of a pre-clinical anti-tumor therapeutic, MT19c...
  34. doi The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload
    Laura M G Meems
    Department of Cardiology, University of Groningen, University Medical Center Groningen, P O Box 30 001, Postal code AB43, 9700 RB Groningen, The Netherlands
    J Steroid Biochem Mol Biol 132:282-9. 2012
    ..We hypothesized that activation of the VDR by paricalcitol would prevent fibrosis and LV diastolic dysfunction in an established murine model of cardiac remodeling...
  35. doi Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice
    Luis E Becker
    Division of Nephrology, Ruperto Carola University, Heidelberg, Germany
    Am J Physiol Renal Physiol 300:F772-82. 2011
    ..While at the dose employed paricalcitol significantly reduced TGF-β expression in plaques, calcitriol in contrast caused significant vascular calcification and elevated expression of related proteins (BMP2, RANKL, and Runx2)...
  36. doi Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial
    Steven Fishbane
    Winthrop University Hospital, Mineola, NY, USA
    Am J Kidney Dis 54:647-52. 2009
    ..Because of this, it could be helpful in treating patients with proteinuric renal diseases. The objective is to determine the effect of oral paricalcitol on protein excretion in patients with proteinuric chronic kidney disease...
  37. doi Suppression of renin-angiotensin gene expression in the kidney by paricalcitol
    Michael Freundlich
    Division of Pediatric Nephrology, Department of Pediatrics, University of Miami, Miami, Florida 33101, USA
    Kidney Int 74:1394-402. 2008
    ..These studies suggest that the beneficial effects of vitamin D receptor activators in experimental chronic renal failure are due, at least in part, to down-regulation of the renal renin-angiotensin system...
  38. pmc Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin
    Xianwu Li
    University of Washington, Seattle, WA 98195, USA
    Arterioscler Thromb Vasc Biol 30:321-6. 2010
    ..Vascular calcification is highly correlated with morbidity and mortality, and it is often associated with inflammation. Vitamin D may regulate vascular calcification and has been associated with cardiovascular survival benefits...
  39. ncbi Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats
    Masahide Mizobuchi
    Renal Division, Washington University School of Medicine, St Louis, MO 63110, USA
    J Am Soc Nephrol 18:1796-806. 2007
    ..1-fold versus NC). Thus, 19-nor can suppress the progression of renal insufficiency via mediation of the TGF-beta signaling pathway, and this effect is amplified when BP is controlled via renin-angiotensin system blockade...
  40. ncbi Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism
    Stuart M Sprague
    Division of Nephrology Hypertension and Department of Medicine, Northwestern University Feinberg School of Medicine, Evanston, Illinois 60201, USA
    Kidney Int 63:1483-90. 2003
    ..A comparative study was undertaken in order to determine whether paricalcitol provides a therapeutic advantage to calcitriol...
  41. pmc Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease
    Jane L Finch
    Renal Division, Washington University Medical School, St Louis, Missouri 63110, USA
    Am J Physiol Renal Physiol 298:F1315-22. 2010
    ..In conclusion, due to its effects on bone and to the hypocalcemia and severe hyperphosphatemia it induces, we believe that cinacalcet should not be used in patients with CKD without further detailed studies...
  42. pmc Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults
    N Binkley
    Osteoporosis Clinical Center and Research Program, University of Wisconsin, Madison, Wisconsin 53705, USA
    J Clin Endocrinol Metab 96:981-8. 2011
    ..Whether ergocalciferol (D(2)) and cholecalciferol (D(3)) are equally effective to increase and maintain serum 25-hydroxyvitamin D [25(OH)D] concentration is controversial...
  43. doi Rapid correction of low vitamin D status in nursing home residents
    R Przybelski
    University of Wisconsin Osteoporosis Clinical Research Program, Madison, WI 53705, USA
    Osteoporos Int 19:1621-8. 2008
    ..This prospective study finds that ergocalciferol 50,000 IU three times weekly for four weeks effectively and safely corrects vitamin D inadequacy in nursing home residents...
  44. ncbi Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport
    Alex J Brown
    Renal Division, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Lab Clin Med 139:279-84. 2002
    ..In summary, the reduced calcemic and phosphatemic activities of 19-norD(2) can be attributed to lower potency in stimulating intestinal calcium and phosphate absorption...
  45. pmc Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients
    Christian S Shinaberger
    Harold Simmons Center for Kidney Disease Research and Epidemiology, Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, CA 90509 2910, USA
    Clin J Am Soc Nephrol 3:1769-76. 2008
    ..It was hypothesized that the ratio of the administered paricalcitol dosage to serum PTH level discloses better the underlying dosage-survival association...
  46. ncbi Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials
    Heike A Bischoff-Ferrari
    Department of Nutrition, Harvard School of Public Health, Boston, Mass 02115, USA
    JAMA 293:2257-64. 2005
    ..The role and dose of oral vitamin D supplementation in nonvertebral fracture prevention have not been well established...
  47. pmc The effect of vitamin D2 and vitamin D3 on intestinal calcium absorption in Nigerian children with rickets
    Tom D Thacher
    Department of Family Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 94:3314-21. 2009
    ..Children with calcium-deficiency rickets have high 1,25-dihydroxyvitamin D values...
  48. ncbi Vitamin D2 is much less effective than vitamin D3 in humans
    Laura A G Armas
    Creighton University, 601 North 30th Street, Suite 4841, Omaha, Nebraska 68131, USA
    J Clin Endocrinol Metab 89:5387-91. 2004
    ..5:1. Vitamin D(2) potency is less than one third that of vitamin D(3). Physicians resorting to use of vitamin D(2) should be aware of its markedly lower potency and shorter duration of action relative to vitamin D(3)...
  49. ncbi Differential effects of vitamin D analogs on vascular calcification
    Anna Cardus
    Department of Medicine, University of Lleida, Lleida, Spain
    J Bone Miner Res 22:860-6. 2007
    ..Calcitriol, but not paricalcitol, increased VSMC calcification in vitro and in vivo independently of calcium and phosphate levels. This increase in calcification was parallel to an increase in the RANKL/OPG ratio...
  50. ncbi Is activated vitamin D supplementation renoprotective?
    Matthew R Weir
    Hypertension 52:211-2. 2008
  51. ncbi Differential effects of vitamin D receptor activators on vascular calcification in uremic rats
    M Mizobuchi
    Renal Division, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Kidney Int 72:709-15. 2007
    ..Hence, different VDRAs have different effects on vascular calcification in uremic rats. The effects are independent of the serum calcium-phosphate product suggesting independent mechanisms...
  52. pmc Antioxidant and renoprotective effects of paricalcitol on experimental contrast-induced nephropathy model
    E Ari
    Department of Nephrology, Van Yuksek Ihtisas Hospital, Van, Turkey
    Br J Radiol 85:1038-43. 2012
    ..The aim of the study was to assess the effect of paricalcitol on the experimental contrast-induced nephropathy (CIN) model. We hypothesised that paricalcitol may prevent CIN...
  53. ncbi VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey
    Mario Cozzolino
    Renal Division, Dipartimento di Medicina, Chirurgia e Odontoiatria, University of Milan, San Paolo Hospital, Milan, Italy
    Nephrol Dial Transplant 27:3588-94. 2012
    ..However, the reason why these patients have higher mortality compared to patients with normal PTH levels has not yet been fully elucidated...
  54. pmc Quantification of 1α,25-dihydroxy vitamin D by immunoextraction and liquid chromatography-tandem mass spectrometry
    Frederick G Strathmann
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA
    Clin Chem 57:1279-85. 2011
    ..We developed a method for simultaneous quantification of 1,25(OH)(2)D(2) and 1,25(OH)(2)D(3) with a 4.6-min instrument cycle time. Results are available 36 h after sample preparation begins...
  55. doi Paricalcitol prevents cisplatin-induced renal injury by suppressing apoptosis and proliferation
    Jeong Woo Park
    Department of Internal Medicine, Chonnam National University Medical School, Gwangju 501 757, Republic of Korea
    Eur J Pharmacol 683:301-9. 2012
    ..Its underlying mechanisms may include inhibition of TGF-β1, mitogen-activated protein kinase signaling, p53-induced apoptosis, and augmentation of p27(kip1)...
  56. ncbi Calcemic activity of 19-Nor-1,25(OH)(2)D(2) decreases with duration of treatment
    A J Brown
    Renal Division, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Am Soc Nephrol 11:2088-94. 2000
    ..In conclusion, the low calcemic activity of 19-norD(2) seems to be due to an acquired, postreceptor resistance of the intestine and bone to chronic treatment with the analog...
  57. doi The role of paricalcitol on proteinuria
    Georgios Aperis
    Nephrology Department, General Hospital of Rhodes, 85100 Rhodes, Greece
    J Ren Care 37:80-4. 2011
    ..However, our study raises a question regarding why some patients do not respond to paricalcitol. Patients with proteinuria due to diabetic nephropathy seem to respond better than patients with glomerulopathy...
  58. doi Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects?
    Rajiv Agarwal
    Indiana University School of Medicine and Richard L Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana 46202, USA
    Kidney Int 77:943-5. 2010
    ..Whether VDRAs will accomplish this goal among proteinuric patients with chronic kidney disease needs to be tested in randomized controlled trials...
  59. ncbi Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis
    Larry A Greenbaum
    Emory University and Children s Healthcare of Atlanta, GA 30322, USA
    Am J Kidney Dis 49:814-23. 2007
    ..Paricalcitol, a selective vitamin D receptor activator, causes less sustained hypercalcemia and increase in Ca x P product than calcitriol and has been used effectively in adult hemodialysis patients...
  60. ncbi Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia
    Eduardo Slatopolsky
    Renal Division, Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Kidney Int 63:2020-7. 2003
    ..Parathyroid gland enlargement and elevated levels of PTH are major contributors to increase bone resorption, a feature of renal osteodystrophy...
  61. doi Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism
    Abdul Halim Abdul Gafor
    Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
    Nephrology (Carlton) 14:488-92. 2009
    ..v. calcitriol or i.v. paricalcitol...
  62. ncbi The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer
    T C Chen
    Vitamin D, Skin and Bone Research Laboratory, Boston University Medical Center, Massachusetts 02118, USA
    Clin Cancer Res 6:901-8. 2000
    ..Both drugs are approved for human use and may be good candidates for human clinical trials in prostate cancer...
  63. ncbi Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer
    Glenn Liu
    University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Clin Cancer Res 8:2820-7. 2002
    ..Whereas the defined maximum tolerated dose was not reached, the recommended Phase II dose was 12.5 microg/day given continuously...
  64. doi Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines
    Laurent Brard
    Department of Obstetrics and Gynecology, Alpert Medical School, Brown University, Providence, RI 02905, USA
    Gynecol Oncol 123:370-8. 2011
    ..This study was designed to evaluate a novel non-hypercalcemic vitamin-D derivative (MT19c) and its anticancer effects in cultured ovarian cancer cell model...
  65. doi The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency
    P Leventis
    Department of Rheumatology, St George s Healthcare NHS Trust, London, UK
    Scand J Rheumatol 38:149-53. 2009
    ..To investigate the practicality and tolerability of high-dose intramuscular (i.m.) vitamin D2 or oral vitamin D3 replacement in vitamin D-insufficient patients, and to evaluate the biochemical efficacy of each formulation...
  66. ncbi Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease
    Dennis Andress
    Department of Medicine, University of Washington, 1660 South Columbian Way, Seattle, WA 98108, USA
    Drugs 67:1999-2012. 2007
    ..Complex nonclassical effects, which are not clearly understood, possibly contribute to the improved survival seen with VDRAs, especially paricalcitol...
  67. pmc Myocardial effects of VDR activators in renal failure
    Masahide Mizobuchi
    Renal Division, Department of Medicine, Washington University St Louis, MO 63110, USA
    J Steroid Biochem Mol Biol 121:188-92. 2010
    ..Paricalcitol may prove to have a substantial beneficial effect on cardiac disease and its outcome in patients with CKD. Prospective randomized studies in CKD patients are necessary to confirm these results...
  68. ncbi Early response to vitamin D2 in children with calcium deficiency rickets
    Tom D Thacher
    Department of Family Medicine, Jos University Teaching Hospital, University of Jos, Jos, Nigeria
    J Pediatr 149:840-4. 2006
    ..To assess the effect of vitamin D(2) administration on serum vitamin D metabolite concentrations in calcium deficiency rickets...
  69. ncbi Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol
    S M Sprague
    Department of Medicine, Division of Nephrology Hypertension, Northwestern University Medical School, Chicago and Evanston, IL, USA
    Am J Kidney Dis 38:S51-6. 2001
    ..0 mg/dL) was greater in those administered calcitriol compared with paricalcitol. In conclusion, our data suggest that paricalcitol reduces PTH levels more rapidly, with fewer episodes of hyperphosphatemia, than intravenous calcitriol...
  70. ncbi Comparative review of the pharmacokinetics of vitamin D analogues
    George R Bailie
    Albany College of Pharmacy, Albany, New York, USA
    Semin Dial 15:352-7. 2002
    ..More studies are warranted to determine the disposition of the vitamin D analogues, especially in selected populations such as pediatric and geriatric dialysis patients...
  71. ncbi Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2
    F Llach
    Division of Nephrology, Newark Beth Israel Medical Center, NJ 07112, USA
    Am J Kidney Dis 32:S48-54. 1998
    ..These results show that paricalcitol safely and effectively reduces iPTH levels in hemodialysis patients with secondary HPT...
  72. ncbi Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol
    J M Repo
    Medical School, University of Tampere, Tampere, Finland
    Kidney Int 72:977-84. 2007
    ..Possible explanations are that aggravated perivascular fibrosis after paricalcitol in renal insufficiency may be due to further suppression of calcitriol, or to a direct effect of the vitamin D analog...
  73. ncbi Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients
    Daniel W Coyne
    Department of Internal Medicine, Renal Division, and the Chromalloy American Kidney Center at Washington University School of Medicine, St Louis, MO, USA
    Am J Kidney Dis 40:1283-8. 2002
    ..The vitamin D analogue 19-nor-1,25(OH)2-vitamin D2 (19-Nor) causes less hypercalcemia and elevated Ca x P, whereas it still suppresses PTH in rats...
  74. ncbi Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease
    Marie Claude Monier-Faugere
    Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington, KY 40536 0084, USA
    Clin J Am Soc Nephrol 2:1255-60. 2007
    ....
  75. ncbi Survival differences between activated injectable vitamin D2 and D3 analogs
    K Kalantar-Zadeh
    Kidney Int 71:827; author reply 827-8. 2007
  76. ncbi Vascular calcification in chronic kidney failure: role of vitamin D receptor
    J Ruth Wu-Wong
    Abbott Laboratories, 100 Abbott Park Rd, Abbott Park, IL 60064, USA
    Curr Opin Investig Drugs 8:237-47. 2007
    ....
  77. pmc Relationship between vitamin D and muscle size and strength in patients on hemodialysis
    Patricia L Gordon
    Department of Physiological Nursing, School of Nursing, University of California at San Francisco, 2 Koret Way, San Francisco, CA 94143, USA
    J Ren Nutr 17:397-407. 2007
    ....
  78. doi Vitamin D and kidney disease
    Wisam Al-Badr
    Division of Nephrology, Saint Louis University, St Louis, Missouri, USA
    Clin J Am Soc Nephrol 3:1555-60. 2008
    ..Further work is required to define the mechanisms involved and to examine the effects of vitamin D therapy on outcomes in randomized, controlled trials...
  79. ncbi Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis
    Yujiro Kida
    N Engl J Med 349:1971-2; author reply 1971-2. 2003
  80. ncbi The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats
    I Lopez
    Department of Medicina y Cirugia Animal, Universidad de Cordoba, Cordoba, Spain
    Kidney Int 73:300-7. 2008
    ..When used in combination with paricalcitol, AMG 641 provided excellent control of secondary hyperparathyroidism and prevented mortality associated with the use of vitamin D derivatives without causing tissue calcification...
  81. ncbi [Vitamine D in patients with osteoporosis: sufficient or necessary?]
    Serge Ferrari
    Service des maladies osseuses Centre collaborateur de I OMS pour la prevention de l ostéoporose, Département de réhabilitation et gériatrie, HUG, 1211 Geneve
    Rev Med Suisse 3:1515-6, 1518-20. 2007
    ..Moreover, the risk of osteoporosis and of fragility fractures may be influenced by genetic variation in the vitamin D receptor (VDR)...
  82. ncbi Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate
    Glenn M Chertow
    Department of Medicine, University of California, San Francisco, School of Medicine, San Francisco, California, USA
    Clin J Am Soc Nephrol 1:305-12. 2006
    ..The long-term effects of this treatment regimen on clinical outcomes should be tested prospectively...
  83. ncbi Calcification inhibitors and Wnt signaling proteins are implicated in bovine artery smooth muscle cell calcification in the presence of phosphate and vitamin D sterols
    V Shalhoub
    Department of Metabolic Disorders, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, USA
    Calcif Tissue Int 79:431-42. 2006
    ..In this study, exposure of BASMCs to phosphate and active vitamin D sterols induced calcification and changes in expression of genes associated with mineralized tissue...
  84. ncbi Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD
    Ziyad Al-Aly
    Division of Nephrology, Saint Louis Veterans Affairs Medical Center, St Louis, MO 63106, USA
    Am J Kidney Dis 50:59-68. 2007
    ..The effect of ergocalciferol administration on serum 25-hydroxyvitamin D and plasma intact parathyroid hormone (PTH) levels in these patients is not known...
  85. ncbi Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone
    Robert A Upton
    Department of Biopharmaceutical Sciences, University of California, San Francisco, CA, USA
    Nephrol Dial Transplant 18:750-8. 2003
    ..This is the first detailed pharmacokinetic report published on the administration of doxercalciferol [1alpha(OH)D(2)] recently introduced to treat secondary hyperparathyroidism...
  86. ncbi [Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient]
    D Brancaccio
    Divisione di Nefrologia e Dialisi, Ospedale San Paolo, Milano, Italy
    G Ital Nefrol 20:S12-6. 2003
    ..In conclusion, a combined use of non calcemic phosphate binders, new vitamin D analogs and calcimimetics should be seriously considered to further improve the already known therapy of secondary hyperparathyroidism in ESRD patients...
  87. ncbi Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis
    Giacomo Colussi
    N Engl J Med 349:1971-2; author reply 1971-2. 2003
  88. doi Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism
    Mario Cozzolino
    University of Milan, S Paolo Hospital, Renal Division, Via A Di Rudini, 8 20142, Milan, Italy
    Expert Opin Pharmacother 9:947-54. 2008
    ..Classically, SHPT is induced by hypocalcemia, hyperphosphatemia, and calcitriol deficiency, that cause not only renal osteodystrophy but also systemic toxicity, particularly cardiovascular disease...
  89. ncbi Paricalcitol as compared with calcitriol in patients undergoing hemodialysis
    Tilman B Drueke
    N Engl J Med 349:496-9. 2003
  90. ncbi Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs
    Diego Brancaccio
    Chair of Nephrology, University of Milan, Ospedale San Paolo, Milan Italy
    J Nephrol 20:3-9. 2007
    ..This review will also elucidate the possible role of paricalcitol - a new vitamin D analog - in conditioning morbidity and mortality of patients on renal replacement therapy (RRT)...
  91. ncbi Improved patient outcomes in chronic kidney disease: optimizing vitamin D therapy
    Frank A Gesek
    Millennium CME Institute, Inc, Hampton, NH, USA
    Nephrol Nurs J 35:5S-22S; quiz 23S. 2008
    ..Vitamin D deficiency is associated with cardiovascular disease and contributes to the high morbidity and mortality in patients with CKD...
  92. ncbi Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease
    Steven Cheng
    Renal Division, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Expert Opin Pharmacother 7:617-21. 2006
    ..Paricalcitol also compares favourably to other oral vitamin D analogues, effectively decreasing parathyroid secretion with less hypercalcaemia and hypercalciuria than other agents...
  93. ncbi A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4
    Hanna Abboud
    University of Texas Health Science Center, San Antonio, Texas, USA
    Am J Nephrol 26:105-14. 2006
    ..Intermittent dosing of calcitriol for secondary hyperparathyroidism (SHPT) has been associated with greater parathyroid hormone (PTH) reduction with fewer calcemic and phosphatemic effects than daily (QD) dosing...
  94. ncbi [The trend in the development of the active vitamin D3 and its analogues]
    Naoko Miwa
    Department of Medicine, Kidney Center, Tokyo Women s Medical University
    Nihon Rinsho 62:364-7. 2004
  95. ncbi Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women
    S R Mastaglia
    Seccion Osteopatias Medicas, Hospital de Clinicas, Universidad de Buenos Aires, Buenos Aires, Argentina
    Eur J Clin Nutr 60:681-7. 2006
    ..Assessment of the effectiveness and safety of high daily 125 microg (5,000 IU) or 250 microg (10,000IU) doses of vitamin D(2) during 3 months, in rapidly obtaining adequate 25 hydroxyvitamin D (25OHD) levels...
  96. ncbi Long-term therapy with paricalcitol for secondary hyperparathyroidism in hemodialysis patients
    A Barton Pai
    College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, USA
    Int J Artif Organs 26:484-90. 2003
    ..This purpose of this study was to determine long-term effects of paricalcitol therapy on parathyroid hormone (PTH) suppression and serum levels of calcium, phosphorus and calcium-phosphorus product (Ca x P)...
  97. ncbi Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer
    Gary G Schwartz
    Department of Cancer Biology, Wake Forest University, Winston Salem, NC 27157, and Nortwest Georgia Oncology Centers, Douglasville, USA
    Clin Cancer Res 11:8680-5. 2005
    ..We assessed the safety and efficacy of the vitamin D analogue, 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol), in patients with androgen-independent prostate cancer...
  98. ncbi Effects of vitamin D compounds on renal and intestinal Ca2+ transport proteins in 25-hydroxyvitamin D3-1alpha-hydroxylase knockout mice
    Joost G J Hoenderop
    Department of Physiology, Nijmegen Centre for Molecular Life Sciences, University Medical Centre Nijmegen, The Netherlands
    Kidney Int 66:1082-9. 2004
    ..Newer vitamin D compounds retain the suppressive action of 1,25(OH)(2)D(3) on the parathyroid glands and may have less Ca(2+)-mobilizing activity, offering potentially safer therapies...
  99. ncbi Differential effects of Vitamin D analogs on bone formation and resorption
    Masaki Nakane
    Abbott Laboratories, R4CM, AP52, 200 Abbott Park Rd, Abbott Park, IL 60064 6217, USA
    J Steroid Biochem Mol Biol 98:72-7. 2006
    ....
  100. ncbi Vitamin D analogs down-regulate plasminogen activator inhibitor-1 in human coronary artery smooth muscle cells
    J Ruth Wu-Wong
    J Thromb Haemost 3:1545-6. 2005
  101. ncbi Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients
    M E Staniforth
    Department of Internal Medicine, Renal Division, Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Nephrol 63:454-60. 2005
    ..Less frequent dosing would be more convenient, require less nursing time, and be an option in other dialysis modalities. No studies have examined the efficacy of once-weekly dosing of paricalcitol...

Research Grants115 found, 100 shown here

  1. Ergocalciferol in ESRD Efficacy Safety and Biology
    Ravi Thadhani; Fiscal Year: 2009
    ..Our study is designed to determine safe and effective ways to raise vitamin D levels while monitoring effects on the immune system. ..
  2. REGULATION OF BONE FORMATION IN RENAL OSTEODYSTROPHY
    ISIDRO SALUSKY; Fiscal Year: 2000
    ..These studies will provide new information about tissue specific modifiers of cancellous bone formation and endochondral bone formation in children with renal osteodystrophy. ..
  3. REGULATION OF BONE FORMATION IN RENAL OSTEODYSTROPHY
    Isidro B Salusky; Fiscal Year: 2004
    ..The result of the study should provide new information on the regulation of bone formation and PTH by different vitamin D sterols in patients with 2-HPT. ..
  4. Evaluation of Vitamin D Requirements During Pregnancy
    Bruce Hollis; Fiscal Year: 2007
    ....
  5. Optimizing Vitamin D Treatment in HIV/AIDS: An RCT
    DOUGLAS THOMAS DIETERICH; Fiscal Year: 2010
    ..Our study will help physicians make evidence-based decisions about the most effective way to use vitamin D in their patients and enable the design of large multi-center trials in the future. ..
  6. Novel biosynthetic pathway for secosteroids and the skin
    Andrzej T Slominski; Fiscal Year: 2010
    ..6. Defining the effect of 7-DHP, its hydroxy and seco-derivatives and of vitamin D (modified or unmodified) on P450scc mediated pregnenolone production from cholesterol. ..
  7. Novel biosynthetic pathway for secosteroids and the skin
    Andrzej Slominski; Fiscal Year: 2007
    ..6. Defining the effect of 7-DHP, its hydroxy and seco-derivatives and of vitamin D (modified or unmodified) on P450scc mediated pregnenolone production from cholesterol. ..
  8. Novel biosynthetic pathway for secosteroids and the skin
    Andrzej Slominski; Fiscal Year: 2009
    ..6. Defining the effect of 7-DHP, its hydroxy and seco-derivatives and of vitamin D (modified or unmodified) on P450scc mediated pregnenolone production from cholesterol. ..
  9. Ergocalciferol in ESRD Efficacy Safety and Biology
    Ravi Thadhani; Fiscal Year: 2010
    ..Our study is designed to determine safe and effective ways to raise vitamin D levels while monitoring effects on the immune system. ..
  10. VITAMIN K AND BONE TURNOVER IN POSTMENOPAUSAL WOMEN
    Neil Binkley; Fiscal Year: 2003
    ..abstract_text> ..
  11. Pathobiology of Kidney Disease: Role of Iron
    Rajiv Agarwal; Fiscal Year: 2007
    ..Novelty and Health Relatedness of the Project: This proposal will provide translational data on the role of intravenous iron to progression of kidney disease in patients with CKD. ..
  12. Hypertension in Hemodialysis Patients
    Rajiv Agarwal; Fiscal Year: 2007
    ..Evaluation of such strategies will improve BP control in hemodialysis patients and, in the long-term, provide cardiovascular protection. ..
  13. Hypertension in Hemodialysis Patients
    Rajiv Agarwal; Fiscal Year: 2010
    ..We hypothesize that that volume control can improve BP and antihypertensive therapy can regress left ventricular hypertrophy in long-term hemodialysis patients. ..
  14. THE PHOTOBIOLOGY OF VITAMIN D3
    Michael Holick; Fiscal Year: 1993
    ....
  15. PTH (7-34) for Chemotherapy alopecia in Breast Cancer
    Michael Holick; Fiscal Year: 2006
    ....
  16. THE PHOTOBIOLOGY OF VITAMIN D
    Michael Holick; Fiscal Year: 2005
    ..Results from this study should provide important new insights into the photoproduction of toxisterols and suprasterols in human skin and provide new information about their potential biologic functions in the skin. ..
  17. PHOTOBIOLOGY OF VITAMIN D
    Michael Holick; Fiscal Year: 2000
    ....
  18. Bone-Sparing by Ca Salts With & Without Extra Phosphorus
    Robert Heaney; Fiscal Year: 2006
    ..abstract_text> ..
  19. BONY EFFECTS OF TRANSIENT NONSKELETAL ILLNESS
    Robert Heaney; Fiscal Year: 2001
    ....
  20. Regulation of Bone Mineralization in Renal Osteodystrophy
    ISIDRO BENJAMIN SALUSKY; Fiscal Year: 2010
    ..Current evidence indicates that severe bone disease and growth retardation are the main long-term consequences of chronic kidney disease since childhood. ..
  21. Molecular Biology of Retinoblastoma
    Daniel Albert; Fiscal Year: 2006
    ..Lastly the potency of the 19-nor compounds wil be compared to standard chemotherapy and their possible synergistic effect in multi-drug treatment established. ..
  22. Anti-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients
    Kamyar Kalantar Zadeh; Fiscal Year: 2007
    ....
  23. Establishing the Vitamin D Requirements During Lactation
    Bruce Hollis; Fiscal Year: 2009
    ..The findings of this study will generate important new information for health care professionals and policy makers with regard to vitamin D requirements and the potential benefit to both mother and infant. ..
  24. MOLECULAR BIOLOGY OF RETINOBLASTOMA AND UYEAL MELANOMA
    Daniel Albert; Fiscal Year: 1993
    ..In addition we have described the inhibition of retinoblastoma growth by vitamin D compounds and sodium butyrate and we will continue to study potential therapeutic strategies in the transgenic mouse model of retinoblastoma...
  25. MOLECULAR BIOLOGY OF RETINOBLASTOMA AND UVEAL MELANOMA
    Daniel Albert; Fiscal Year: 2000
    ..5. We will characterize pigmented tumors developing in the eyes of mice expressing SV40-T antigen (SV40-Tag) under the control of the mouse tyrosinase gene, and establish the relevance of these mice as a model for human uveal melanoma. ..
  26. Establishing the Vitamin D Requirements During Lactation
    Bruce Hollis; Fiscal Year: 2009
    ..The findings of this study will generate important new information for health care professionals and policy makers with regard to vitamin D requirements and the potential benefit to both mother and infant. ..
  27. Musculoskeletal Disorder in Dialysis Patients
    Sharon Moe; Fiscal Year: 2007
    ..These studies, Dr. Moe, and the strong clinical research support at Indiana Unviersity provide an excellent training environment for the development of future investigators in patient oriented research. ..
  28. Bisphosphonates in the treatment of chronic kidney disease-mineral bone disease
    Sharon M Moe; Fiscal Year: 2010
    ..Both of these problems may be linked. The purpose of this study is to determine if a commonly used group of drugs, bisphosphonates, may help both bone and heart/blood vessel disease and determine the mechanism the drugs work. ..
  29. THE MOLECULAR BIOLOGY OF RETINOBLASTOMA
    Daniel Albert; Fiscal Year: 2005
    ..2d) Determine whether I a-hydroxy-D2 and 16,23 -D3 inhibit angiogenesis in a transgenic mouse model. These studies will complete the pre-clinical investigation of the efficacy of vitamin D analogs for human treatment. ..
  30. ROLE OF PARATHYROID HORMONE IN RENAL OSTEODYSTROPHY
    Isidro B Salusky; Fiscal Year: 2009
    ..The results of the study should provide new information on the relationship between PTH and bone formation in CKD and they are likely to have important implications for the diagnosis and treatment of renal osteodystrophy. ..